With new technologies and discoveries advancing rapidly, the life sciences sector is growing faster than ever. BioTech, pharmaceutical, and MedTech companies need to make sure that their fundraising, innovation, and strategic partnership efforts are conducted smoothly and at maximum efficiency. When it comes to starting and building a medical device company, a strong patent strategy tied to business goals can be the driving force behind venture capital investment, strategic collaborations, mergers and acquisitions. In order to safeguard its intellectual property (IP), every MedTech startup should consider protecting and leveraging its innovations as soon as possible.
In this webinar, join in a discussion between Dr Andrew T. Serafini, Partner and Mr Patrick Ngeim, Senior Associate at Kilpatrick Townsend on strategies for protecting innovations utilising software inventions in the U.S., including Artificial Intelligence (AI) innovation in the life science space. They will be addressing some of the best practices for overcoming various US Patent and Trademark Office (USPTO) hurdles for patentability, its requirements and strategies to meet the current demands.
Key Takeaways:
- Best practices for overcoming hurdles for patentability
- Strategies to meet the current “patentability” requirements
- Increase in USPTO AI patent filings
- IP strategies regarding patent protections for AI and other areas in the life sciences
- Training of an AI, the use of the AI, and/or the specific models of the AI
Event Details
Wednesday, December 2, 2020
Webinar
Speakers
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
